Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

Clinical trial NCT07532525 · RECRUITING

Trial details

NCT number: NCT07532525
Sponsor: University of Michigan Rogel Cancer Center
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Recurrent B Acute Lymphoblastic Leukemia Recurrent B-Cell Non-Hodgkin Lymphoma Refractory B Acute Lymphoblastic Leukemia Refractory B-Cell Non-Hodgkin Lymphoma

Start date: 2026-09-01
Primary completion: 2027-10-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.